Anne Jacquet-Bescond

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

Mike F. Burbridge, Céline Bossard, Carine Saunier et al. · Molecular Cancer Therapeutics · 2013 · 86 citations

Chemoprevention Strategy, Immunology, Cancer Biology +18

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms

Ashfaq Ali, Olivier Bluteau, Kahia Messaoudi et al. · Cell Death and Disease · 2013 · 38 citations · Full text

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

Mélanie Gressette, Benjamin Vérillaud, Anne-Sophie Jimenez-Pailhès et al. · PLoS ONE · 2014 · 36 citations · Full text

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models

Federica Guffanti, Rosaria Chilà, Ezia Bello et al. · Neoplasia · 2016 · 34 citations · Full text

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

Sylvain Fouliard, Renata Robert, Anne Jacquet-Bescond et al. · European Journal of Cancer · 2013 · 33 citations

Administration Schedule, Biochemistry, Medicine +8